Gland Pharma Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Gland Pharma Limited - overview
Established
1978
Location
Hyderabad, Telangana, India
Primary Industry
Pharmaceuticals
About
Based in Hyderabad, India, and founded in 1978 Gland Pharma Limited bears the ticker symbol NSE: GLAND operates as a manufacturer of global injectables. And it follows the CDMO business model. As of 2022, the company’s employee base includes 4,639 employees. PVN Raju and Dr.
Ravi Penmetsa founded the firm. As of 2022, the company is headed by its CEO Srinivas Sadu. The company offers complex injectables which include NCE-1s, First-to-File products, and 505(b)(2) filings across sterile injectables, oncology, and ophthalmic segments. Additionally, it offers a vast array of products across several therapeutic segments including anti-infectives, anti-coagulants, antidotes, anti-malarial, fertility supplements, etc.
The firm delivered its products through liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. The firm’s business scope covers 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. The company generated revenue of INR 44,007 during the financial year of 2021-2022 from existing and newly launched products.
Primary Industry
Pharmaceuticals
Sub Industries
Medical Equipment Distributors, Pharmaceutical Research & Development
Website
http://www.glandpharma.com
Verticals
Manufacturing
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Gland Pharma Limited - timeline of key events
Gland Pharma Limited - financials
| Fiscal Year Ended | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 |
|---|---|---|---|---|---|---|
| Revenue (USD) | 16,228,930,000 | 20,442,030,000 | 26,332,400,000 | - | - | - |
| % Revenue Growth (YoY) | - | 26.0% | 28.8% | - | - | - |
| EBITDA (USD) | 5,567,260,000 | 7,285,630,000 | 10,431,490,000 | - | - | - |
| Operating Income (USD) | 4,785,180,000 | 6,466,040,000 | 9,485,620,000 | - | - | - |
| Operating Margin | 29.5% | 31.6% | 36.0% | - | - | - |
| % EBITDA Margin | 34.3% | 35.6% | 39.6% | - | - | - |
| NET Income (USD) | 3,211,140,000 | 4,519,070,000 | 7,728,580,000 | - | - | - |
| % Net Margin | 19.8% | 22.1% | 29.4% | - | - | - |
Gland Pharma Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Announced | Cenexi Services S.A.S.A.U. | - | ||||||||
| IPO | Completed | Gland Pharma Limited | - | ||||||||
| Trade Sale | Completed | Gland Pharma Limited | - | ||||||||
| Secondary Buyout | Completed | Gland Pharma Limited | - | ||||||||
| Trade Sale | Completed | Gland Pharma Limited | - |
Displaying 1 - 5 of 6
Gland Pharma Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.